Key result
Diabetes did not influence the performance of MR-proANP and MR-proADM for acute heart failure diagnosis or 90-day all-cause death in patients with acute dyspnea.
Why the study?
Does diabetes affect the diagnostic and prognostic performance of MR-proANP and MR-proADM in patients with acute dyspnea?
Observational
Does diabetes affect the diagnostic and prognostic performance of MR-proANP and MR-proADM in patients with acute dyspnea?
Diabetes does not confound the diagnostic and prognostic utility of MR-proANP and MR-proADM for acute heart failure in patients presenting with acute dyspnea.
Answers are grounded in this paper and cite their sources.
Supports reliable MR-proANP/MR-proADM use irrespective of diabetes in acute dyspnea; leaves open prospective validation before routine adoption.
Serum mid-regional pro-atrial natriuretic peptide (MR-proANP) and pro-adrenomedullin (MR-proADM) are novel biomarkers for acute heart failure (AHF). Like other AFH biomarkers, the performance of these tests are affected by the presence of clinical variables such as renal failure and obesity. In a substudy of the Biomarkers from Acute Heart Failure Study, we show that diabetes did not influence the performance of these markers with regards to AHF diagnosis or 90-day all cause death. However, in patients without AHF, increased MR-proADM alone was associated with the presence of diabetes.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2012) conducted an observational in Acute dyspnea. Diabetes vs. No diabetes was evaluated on Acute heart failure diagnosis or 90-day all cause death. Diabetes did not influence the performance of MR-proANP and MR-proADM for acute heart failure diagnosis or 90-day all-cause death in patients with acute dyspnea.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: